Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ambicare Health Ltd.

www.ambicarehealth.com

Latest From Valeant Pharmaceuticals International Inc.

Deal Watch: Valeant Continues Divestment Spree By Selling Obagi At A Loss

Emergent reveals acquisition of GSK's anthrax therapy raxibacumab days after a vaccine deal with Sanofi. Telix licenses PSMA antibodies from Abzena, while PeptiDream and Kleo sign an immuno-oncology pact.

Deals Business Strategies

Keeping Track: Tremfya Clears FDA; Dextenza Amendment Is Too Late; Emicizumab, Abemaciclib Filed

The latest drug development news and highlights from our US FDA Performance Tracker.

Regulation Research & Development

J&J's First-In-Class Tremfya Poised To Join A Crowded Psoriasis Market

FDA approved Johnson & Johnson's IL-23 blocker guselkumab July 13; the drug will be priced at an annual wholesale acquisition cost of $58,100, roughly in line with the currently marketed IL-17 blocker Cosentyx.

Launches Dermatology

Deals Shaping The Medical Industry, July 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2017.

Deals BioPharmaceutical
See All

Company Information

  • Industry
  • Medical Devices
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Alias(es)
  • Lumicure Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Ambicare Health Ltd.
  • Senior Management
  • Ian T Muirhead, CEO
    Andrew McNeill, PhD, Dir. & Principal Scientist
  • Contact Info
  • Ambicare Health Ltd.
    Phone: (44) 771 498 0617
    Kinburn Castle
    St. Andrews
    Fife, KY16 9DR
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register